BridgeBio Pharma, Inc. (BBIO) › Capital ExpendituresBridgeBio Pharma, Inc. (BBIO) — Capital ExpendituresAnnual figures by period end, from SEC filings.2017-12-31: $464.0K2018-12-31: $2.18M2019-12-31: $2.64M2020-12-31: $7.52M2021-12-31: $13.25M2022-12-31: $4.82M2023-12-31: $1.31M2024-12-31: $933.0K2025-12-31: $1.10M$1.10M2017-12-31Capital Expenditures (USD)2025-12-31Period endedCapital ExpendituresChange YoYSource filing2025-12-31$1.10M+17.6%2026-02-24From 2025-01-012024-12-31$933.0K-28.6%2026-02-24From 2024-01-012023-12-31$1.31M-72.9%2026-02-24From 2023-01-012022-12-31$4.82M-63.6%2025-02-20From 2022-01-012021-12-31$13.25M+76.2%2024-02-22From 2021-01-012020-12-31$7.52M+185.0%2023-02-23From 2020-01-012019-12-31$2.64M+21.1%2022-02-25From 2019-01-012018-12-31$2.18M+369.4%2021-02-25From 2018-01-012017-12-31$464.0K—2020-03-03From 2017-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)